retatrutide phase 2 study results Perceived benefits of treatment for obesity with retatrutide: A qualitative of patients in a clinical trial Lilly's triple agonist achieves 16.8%

As awareness regarding the health impacts of obesity and diabetes increases and funding continues to flow, the market for GLP-1 receptor agonists is poised for substantial growth in the coming years

Each degree above 8C reduces functional half-life by approximately 18 hoursat 15C, the peptide degrades to subtherapeutic levels within 48 hours

Once-weekly GLP-1 injections such as semaglutide and dulaglutide can be administered at any time of day, but should be given on the same day each week for consistency

These medications are intended to be lifelong, and to be used in addition to a healthful lifestyle

(2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes